Microbiome-guided inhaled antibiotic prophylaxis

Phase 2Small molecule

Microbiome-guided inhaled antibiotic prophylaxis is one of 10 small molecule programs targeting Ventilator-Associated Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventilator-Associated PneumoniaNot yet recruiting

Ventilator-Associated PneumoniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Ventilator-Associated Pneumonia

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

3 2

Merrem

BB. Braun Medical Inc.

Approved

2 3

Amikin

IInsmed Incorporated

Approved

1 4

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 5

Bactrim

UUniversity of California, San Francisco

Phase 3

1 6

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Antibiotic

Pfizer

Preclinical

1 8

Microbiome-guided inhaled antibiotic prophylaxis

UUniversity of Calgary

Phase 2

1 9

Bacteriophage

AAdaptive Phage Therapeutics, Inc.

Preclinical

1 10

Beta Lactam Antibiotics

OOregon Health and Science University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Ventilator-Associated Pneumonia

NCT07463339

Clinical

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial

Not yet recruiting·UUniversity of Calgary·Phase 2·NCT07463339·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microbiome-guided inhaled antibiotic prophylaxis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microbiome-guided inhaled antibiotic prophylaxis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microbiome-guided inhaled antibiotic prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Calgary

Microbiome-guided inhaled antibiotic prophylaxis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

References

Drug Info

Quick Facts

Related News